Cornercap Investment Counsel Inc. Makes New $216,000 Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Cornercap Investment Counsel Inc. purchased a new position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 61,601 shares of the biotechnology company’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ALDX. JPMorgan Chase & Co. lifted its holdings in shares of Aldeyra Therapeutics by 21.3% in the first quarter. JPMorgan Chase & Co. now owns 22,835 shares of the biotechnology company’s stock worth $101,000 after buying an additional 4,012 shares in the last quarter. Raymond James & Associates lifted its position in shares of Aldeyra Therapeutics by 21.2% in the first quarter. Raymond James & Associates now owns 26,306 shares of the biotechnology company’s stock worth $117,000 after buying an additional 4,609 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Aldeyra Therapeutics by 12.2% during the first quarter. Bank of New York Mellon Corp now owns 209,815 shares of the biotechnology company’s stock valued at $932,000 after buying an additional 22,748 shares during the last quarter. Rhumbline Advisers grew its holdings in Aldeyra Therapeutics by 11.7% during the 1st quarter. Rhumbline Advisers now owns 47,596 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 4,996 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Aldeyra Therapeutics by 5.2% in the 1st quarter. Vanguard Group Inc. now owns 2,961,635 shares of the biotechnology company’s stock worth $13,165,000 after acquiring an additional 147,711 shares during the last quarter. 59.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aldeyra Therapeutics

In other news, CEO Todd C. Brady sold 97,914 shares of Aldeyra Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the sale, the chief executive officer now directly owns 1,556,622 shares in the company, valued at $5,090,153.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of Aldeyra Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the sale, the chief executive officer now owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Perceptive Advisors Llc purchased 37,712 shares of the company’s stock in a transaction on Friday, April 5th. The shares were purchased at an average price of $4.74 per share, for a total transaction of $178,754.88. Following the purchase, the insider now owns 9,275,851 shares in the company, valued at approximately $43,967,533.74. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 355,933 shares of company stock worth $1,473,245. 7.30% of the stock is owned by corporate insiders.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX opened at $3.97 on Thursday. The firm has a market capitalization of $233.83 million, a P/E ratio of -6.20 and a beta of 1.51. The business’s 50-day moving average is $3.56 and its 200 day moving average is $3.28. Aldeyra Therapeutics, Inc has a 1 year low of $1.42 and a 1 year high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.13. On average, analysts expect that Aldeyra Therapeutics, Inc will post -0.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. StockNews.com upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 29th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd. Finally, Oppenheimer upgraded shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday, April 3rd.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.